Previous 10 | Next 10 |
Kura Oncology (NASDAQ:KURA) announces that the FDA has placed the KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory acute myeloid leukemia (AML) on a partial clinical hold. Shares down 35.2% premarket at $10.75. The partial clinical hold was initiated follow...
SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed the ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Image source: The Motley Fool. Kura Oncology, inc (NASDAQ: KURA) Q3 2021 Earnings Call Nov 4, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Kura Oncology, inc (KURA) Q3 2021 Earnings Call Transcript
Kura Oncology (NASDAQ:KURA): Q3 GAAP EPS of -$0.50 beats by $0.04. Cash, cash equivalents and short-term investments of $543.45M. Press Release For further details see: Kura Oncology EPS beats by $0.04
– Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML – – ASH presentation to highlight molecular mechanisms of activity for KO-539 and potential for synergistic activity in combination with ve...
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Credit Suisse 30 th Annual Healthca...
SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2021 financial results after t...
A group of small biotech companies are warning President Biden, Rep. Nancy Pelosi (D-Calif.), Sen. Chuck Schumer (D.-N.Y.) and other top lawmakers about the negative effects a proposed drug pricing bill would have on their industry. In a letter, they say that government-dictated prices for dr...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KURA on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. KURA was trading at $21.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases ...